Preetiparna Parida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Preetiparna Parida has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Mahadev Rao
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India
4 shared publications - Rama Rao Damerla
Department of Medical Genetics, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India
4 shared publications - Shirley Lewis
Department of Radiation Oncology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India
3 shared publications - Chiranjay Mukhopadhyay
Manipal Institute of Virology, Manipal Academy of Higher Education
2 shared publications - Prasad Varamballi
Manipal Institute of Virology, Manipal Academy of Higher Education (MAHE), Manipal, India
2 shared publications - Sudheesh Nittur
Manipal Institute of Virology, Manipal Academy of Higher Education
2 shared publications
Latest Publications
- Open Access
- 29 January 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 220, 105161
Diagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis
- 29 January 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 220, 105161
Open AccessDiagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis
- Open Access
- 9 January 2026
- Published by Taylor & Francis in Critical Public Health
- Vol. 36 (1)
Clinical and genomic epidemiology of Rubella virus in India – a retrospective study
- 9 January 2026
- Published by Taylor & Francis in Critical Public Health
- Vol. 36 (1)
Open AccessClinical and genomic epidemiology of Rubella virus in India – a retrospective study
- Open Access
- 24 May 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 316, 144447
An allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients
- 24 May 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 316, 144447
Open AccessAn allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients
- Open Access
Novel nanopore sequencing method for determining Human Papillomavirus integrations in tumors without the need for whole genome sequencing
Human papillomaviral (HPV) integrations into host human genome, a key event in cervical carcinogenesis, are currently mapped through laborious and expensive sequencing methodologies. We developed and validated a novel library preparation strategy for nanopore sequencing to generate long targeted reads with HPV and human chimeric sequences. Using this strategy, we validated known HPV integrations in HeLa (HPV18) and SiHa (HPV16) cell lines. We also mapped integration sites in five HPV+ cervical cancer patients, which were confirmed by whole genome and Sanger sequencing. Our nanopore-based method provides a precise and efficient strategy to capture HPV integrations crucial for understanding tumorigenesis.
Open AccessNovel nanopore sequencing method for determining Human Papillomavirus integrations in tumors without the need for whole genome sequencing
Human papillomaviral (HPV) integrations into host human genome, a key event in cervical carcinogenesis, are currently mapped through laborious and expensive sequencing methodologies. We developed and validated a novel library preparation strategy for nanopore sequencing to generate long targeted reads with HPV and human chimeric sequences. Using this strategy, we validated known HPV integrations in HeLa (HPV18) and SiHa (HPV16) cell lines. We also mapped integration sites in five HPV+ cervical cancer patients, which were confirmed by whole genome and Sanger sequencing. Our nanopore-based method provides a precise and efficient strategy to capture HPV integrations crucial for understanding tumorigenesis.
- Open Access
- 2 September 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2398719
Molecular detection and genotyping of HMPV in patients with severe acute respiratory infection in India
Human metapneumovirus (HMPV) is a common respiratory pathogen that causes respiratory tract infections. In India, HMPV has been identified as one of the leading causes of morbidity and mortality in infants and young children with respiratory tract infections. The most reported sublineages of HMPV in India are B1, B2, A2b and A2c. A retrospective study was conducted to determine the circulating genotypes of HMPV among SARI cases from January 2016 to December 2018. Positive throat swab samples were confirmed with real-time RT-PCR. Subsequently, these samples were analysed using semi-nested conventional RT-PCR targeting the G gene, followed by sequencing and phylogenetic analysis. Clinical data analysis was also performed using SPSS 15.0 software. All 20 samples from the SARI cases were classified under the A2c sublineage of HMPV. Phylogenetic analysis indicated that these strains were genetically related to those circulating in Japan, China, and Croatia. Among the samples, ten showed 111-nucleotide duplications, while the other ten had 180-nucleotide duplications. Clinical analysis showed that four cases had coinfections with other pathogens. Our extensive analysis of patient samples determined that HMPV, especially the A2c genotype, significantly contributed to SARI cases within our study population, which signifies the importance of considering HMPV as a probable aetiological agent when investigating SARI outbreaks.
- 2 September 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2398719
Open AccessMolecular detection and genotyping of HMPV in patients with severe acute respiratory infection in India
Human metapneumovirus (HMPV) is a common respiratory pathogen that causes respiratory tract infections. In India, HMPV has been identified as one of the leading causes of morbidity and mortality in infants and young children with respiratory tract infections. The most reported sublineages of HMPV in India are B1, B2, A2b and A2c. A retrospective study was conducted to determine the circulating genotypes of HMPV among SARI cases from January 2016 to December 2018. Positive throat swab samples were confirmed with real-time RT-PCR. Subsequently, these samples were analysed using semi-nested conventional RT-PCR targeting the G gene, followed by sequencing and phylogenetic analysis. Clinical data analysis was also performed using SPSS 15.0 software. All 20 samples from the SARI cases were classified under the A2c sublineage of HMPV. Phylogenetic analysis indicated that these strains were genetically related to those circulating in Japan, China, and Croatia. Among the samples, ten showed 111-nucleotide duplications, while the other ten had 180-nucleotide duplications. Clinical analysis showed that four cases had coinfections with other pathogens. Our extensive analysis of patient samples determined that HMPV, especially the A2c genotype, significantly contributed to SARI cases within our study population, which signifies the importance of considering HMPV as a probable aetiological agent when investigating SARI outbreaks.
- Open Access
Increased Gene Expression of C1orf74 Is Associated with Poor Prognosis in Cervical Cancer
C1orf74, also known as URCL4, has been reported to have higher expression and be associated with poor prognosis in lung adenocarcinoma patients, and its role in regulation of the EGFR/AKT/mTORC1 pathway has been recently elucidated. In the current study, we used publicly available data and experimental validation of C1orf74 gene expression and its association with prognosis in cervical cancer patients. qRT-PCR was performed using RNA from cervical cancer cell lines and twenty-five cervical cancer patients. Data from TNMplot revealed that mRNA expression of the C1orf74 gene in primary tumor tissues, as well as metastatic tissues from cervical cancer patients, was significantly higher compared to normal cervical tissues. HPV-positive tumors had higher expression of this gene compared to HPV-negative tumors. qPCR analysis also demonstrated higher expression of C1orf74 in HPV-positive cervical cancer cell lines and most cervical cancer patients. The promoter methylation levels of the C1orf74 gene in cervical cancer tissues were lower compared to normal cervical tissues (p < 0.05). Collectively, our study indicates that higher expression of the C1orf74 gene caused by hypomethylation of its promoter is associated with poor overall survival in cervical cancer patients. Thus, C1orf74 is a novel prognostic marker in cervical cancer.
Open AccessIncreased Gene Expression of C1orf74 Is Associated with Poor Prognosis in Cervical Cancer
C1orf74, also known as URCL4, has been reported to have higher expression and be associated with poor prognosis in lung adenocarcinoma patients, and its role in regulation of the EGFR/AKT/mTORC1 pathway has been recently elucidated. In the current study, we used publicly available data and experimental validation of C1orf74 gene expression and its association with prognosis in cervical cancer patients. qRT-PCR was performed using RNA from cervical cancer cell lines and twenty-five cervical cancer patients. Data from TNMplot revealed that mRNA expression of the C1orf74 gene in primary tumor tissues, as well as metastatic tissues from cervical cancer patients, was significantly higher compared to normal cervical tissues. HPV-positive tumors had higher expression of this gene compared to HPV-negative tumors. qPCR analysis also demonstrated higher expression of C1orf74 in HPV-positive cervical cancer cell lines and most cervical cancer patients. The promoter methylation levels of the C1orf74 gene in cervical cancer tissues were lower compared to normal cervical tissues (p < 0.05). Collectively, our study indicates that higher expression of the C1orf74 gene caused by hypomethylation of its promoter is associated with poor overall survival in cervical cancer patients. Thus, C1orf74 is a novel prognostic marker in cervical cancer.